{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:14:26Z","timestamp":1792822466064,"version":"4.5.0"},"reference-count":56,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-19 CE14-0006-03"],"award-info":[{"award-number":["ANR-19 CE14-0006-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006021","name":"Direction G\u00e9n\u00e9rale de l\u2019Armement","doi-asserted-by":"publisher","award":["PhD grant"],"award-info":[{"award-number":["PhD grant"]}],"id":[{"id":"10.13039\/501100006021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","award":["PhD grant"],"award-info":[{"award-number":["PhD grant"]}],"id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Many autoimmune disorders such as psoriasis lead to the alteration of skin components which generally manifests as unwanted topical symptoms. One of the most widely approved psoriasis-like animal models is the imiquimod (IMQ)-induced mouse model. This representation mimics various aspects of the complex cutaneous pathology and could be appropriate for testing topical treatment options. We perform a thorough characterization of this model by assessing some parameters that are not fully described in the literature, namely a precise description of skin disruption. It was evaluated by transepidermal water loss measurements and analyses of epidermis swelling as a consequence of keratinocyte hyperproliferation. The extent of neo-angiogenesis and hypervascularity in dermis were highlighted by immunostaining. Moreover, we investigated systemic inflammation through cytokines levels, spleen swelling and germinal centers appearance in draining lymph nodes. The severity of all parameters was correlated to IMQ concentration in skin samples. This study outlines new parameters of interest useful to assess this model. We highlight the skin barrier disruption and report a systemic inflammatory reaction occurring at distance both in spleen and lymph nodes. These newly identified biological endpoints could be exploited to investigate the efficacy of therapeutic candidates for psoriasis and more extensively for several other skin inflammatory diseases.<\/jats:p>","DOI":"10.3390\/pharmaceutics12090789","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T21:13:42Z","timestamp":1597958022000},"page":"789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":176,"title":["Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model"],"prefix":"10.3390","volume":"12","author":[{"given":"Mehwish","family":"Jabeen","sequence":"first","affiliation":[{"name":"UMR 5305: Laboratoire de Biologie Tissulaire et d\u2019Ing\u00e9nierie Th\u00e9rapeutique, CNRS\/Universit\u00e9 Claude Bernard Lyon 1, Institut de Biologie et Chimie des Prot\u00e9ines, 7 passage du Vercors, 69367 Lyon CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Boisgard","sequence":"additional","affiliation":[{"name":"UMR 5305: Laboratoire de Biologie Tissulaire et d\u2019Ing\u00e9nierie Th\u00e9rapeutique, CNRS\/Universit\u00e9 Claude Bernard Lyon 1, Institut de Biologie et Chimie des Prot\u00e9ines, 7 passage du Vercors, 69367 Lyon CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-8561","authenticated-orcid":false,"given":"Alix","family":"Danoy","sequence":"additional","affiliation":[{"name":"UMR 5305: Laboratoire de Biologie Tissulaire et d\u2019Ing\u00e9nierie Th\u00e9rapeutique, CNRS\/Universit\u00e9 Claude Bernard Lyon 1, Institut de Biologie et Chimie des Prot\u00e9ines, 7 passage du Vercors, 69367 Lyon CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima","family":"El Kholti","sequence":"additional","affiliation":[{"name":"UMR 5305: Laboratoire de Biologie Tissulaire et d\u2019Ing\u00e9nierie Th\u00e9rapeutique, CNRS\/Universit\u00e9 Claude Bernard Lyon 1, Institut de Biologie et Chimie des Prot\u00e9ines, 7 passage du Vercors, 69367 Lyon CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Salvi","sequence":"additional","affiliation":[{"name":"UMR CNRS 5305, Pharmacie Clinique, Pharmacocin\u00e9tique et Evaluation du M\u00e9dicament, Universit\u00e9 de Lyon, Universit\u00e9 Lyon 1, 69373 Lyon CEDEX 08, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselyne","family":"Boulieu","sequence":"additional","affiliation":[{"name":"UMR CNRS 5305, Pharmacie Clinique, Pharmacocin\u00e9tique et Evaluation du M\u00e9dicament, Universit\u00e9 de Lyon, Universit\u00e9 Lyon 1, 69373 Lyon CEDEX 08, France"},{"name":"Hospices Civils de Lyon, Groupement Hospitalier Edouard Herriot, Laboratoire de Biologie M\u00e9dicale Multi Sites du CHU de Lyon, unit\u00e9 de Pharmacocin\u00e9tique Clinique, 69002 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Fromy","sequence":"additional","affiliation":[{"name":"UMR 5305: Laboratoire de Biologie Tissulaire et d\u2019Ing\u00e9nierie Th\u00e9rapeutique, CNRS\/Universit\u00e9 Claude Bernard Lyon 1, Institut de Biologie et Chimie des Prot\u00e9ines, 7 passage du Vercors, 69367 Lyon CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Verrier","sequence":"additional","affiliation":[{"name":"UMR 5305: Laboratoire de Biologie Tissulaire et d\u2019Ing\u00e9nierie Th\u00e9rapeutique, CNRS\/Universit\u00e9 Claude Bernard Lyon 1, Institut de Biologie et Chimie des Prot\u00e9ines, 7 passage du Vercors, 69367 Lyon CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8880-3048","authenticated-orcid":false,"given":"Myriam","family":"Lamrayah","sequence":"additional","affiliation":[{"name":"UMR 5305: Laboratoire de Biologie Tissulaire et d\u2019Ing\u00e9nierie Th\u00e9rapeutique, CNRS\/Universit\u00e9 Claude Bernard Lyon 1, Institut de Biologie et Chimie des Prot\u00e9ines, 7 passage du Vercors, 69367 Lyon CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.12788\/j.sder.0009","article-title":"Quality-of-life effects of common dermatological diseases","volume":"32","author":"Ahmed","year":"2013","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/jid.2012.318","article-title":"An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling","volume":"133","author":"Karbach","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Mourits","year":"2009","journal-title":"J. Immunol."},{"key":"ref_5","first-page":"854","article-title":"Upregulation of PI3K\/AKT\/mTOR, FABP5 and PPAR\u03b2\/\u03b4 in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model","volume":"96","author":"Chamcheu","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.phrs.2015.06.001","article-title":"Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC\/IL-17A pathway modulation","volume":"99","author":"Nadeem","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lin, Y.-K., Yang, S.-H., Chen, C.-C., Kao, H.-C., and Fang, J.-Y. (2015). Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137890"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejpb.2016.09.021","article-title":"Innovative drug vehicle for local treatment of inflammatory skin diseases: Ex vivo and in vivo screening of five topical formulations containing poly(lactic acid) (PLA) nanoparticles","volume":"116","author":"Boisgard","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2017.03.385","article-title":"Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel","volume":"254","author":"Sun","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"118623","DOI":"10.1016\/j.ijpharm.2019.118623","article-title":"Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model","volume":"569","author":"Bahramizadeh","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1080\/03639045.2019.1576722","article-title":"Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model","volume":"45","author":"Sathe","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2147\/IJN.S246783","article-title":"Cyclodextrin-Modified CeO2 Nanoparticles as a Multifunctional Nanozyme for Combinational Therapy of Psoriasis","volume":"15","author":"Wu","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.burns.2016.04.018","article-title":"Transepidermal water loss measured with the Tewameter TM300 in burn scars","volume":"42","author":"Gardien","year":"2016","journal-title":"Burns"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113295","DOI":"10.1016\/j.jpba.2020.113295","article-title":"In vitro and in vivo trans-epidermal water loss evaluation following topical drug delivery systems application for pharmaceutical analysis","volume":"186","author":"Cristiano","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1354\/vp.45-4-563","article-title":"Review paper: Preclinical models of psoriasis","volume":"45","author":"Danilenko","year":"2008","journal-title":"Vet. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","article-title":"Angiogenesis drives psoriasis pathogenesis","volume":"90","author":"Heidenreich","year":"2009","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0955-0674(03)00100-5","article-title":"PECAM-1: Old friend, new partners","volume":"15","author":"Ilan","year":"2003","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"C1181","DOI":"10.1152\/ajpcell.00524.2001","article-title":"Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration","volume":"282","author":"Cao","year":"2002","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/jcmm.12601","article-title":"Telocyte dynamics in psoriasis","volume":"19","author":"Manole","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1111\/j.1600-0625.2009.01016.x","article-title":"Functional characterization of T cells differentiated in vitro from bone marrow-derived CD34 cells of psoriatic patients with family history","volume":"19","author":"Zhang","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/0377-4929.94857","article-title":"Immunohistochemical study of osteopontin, Ki-67, and CD34 of psoriasis in Mansoura, Egypt","volume":"55","author":"Amin","year":"2012","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1051\/bmdcn\/2019090426","article-title":"Immunohistochemical expression of P53, Ki-67, and CD34 in psoriasis and psoriasiform dermatitis","volume":"9","author":"Ramezani","year":"2019","journal-title":"Biomedicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Calautti, E., Avalle, L., and Poli, V. (2018). Psoriasis: A STAT3-Centric View. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010171"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41419-019-1510-8","article-title":"Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2018.01.048","article-title":"Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes","volume":"824","author":"Kuang","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/jid.2010.255","article-title":"Stat3 as a therapeutic target for the treatment of psoriasis: A clinical feasibility study with STA-21, a Stat3 inhibitor","volume":"131","author":"Miyoshi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1084\/jem.179.3.1059","article-title":"Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo","volume":"179","author":"Bogen","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/1346-8138.13695","article-title":"Involvement of high mobility group box-1 in imiquimod-induced psoriasis-like mice model","volume":"44","author":"Chen","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1189\/jlb.3MA0217-054RR","article-title":"Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: Focus on innate myeloid cells","volume":"102","author":"Costa","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","article-title":"Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors","volume":"140","author":"Gilliet","year":"2004","journal-title":"Arch. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/bmc.1075","article-title":"Development and validation of HPLC method for imiquimod determination in skin penetration studies","volume":"22","author":"Martins","year":"2008","journal-title":"Biomed. Chromatogr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-59745-447-6_5","article-title":"Approaches to determine expression of inflammatory cytokines","volume":"511","author":"Amsen","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.4049\/jimmunol.1402071","article-title":"MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life","volume":"194","author":"Eberhardt","year":"2015","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.1402604","article-title":"Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination","volume":"195","author":"Lofano","year":"2015","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jconrel.2016.07.027","article-title":"Nanocarriers for drug delivery into and through the skin-Do existing technologies match clinical challenges?","volume":"242","author":"Vogt","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D39SH763NC","article-title":"Topical delivery of active principles: The field of dermatological research","volume":"16","author":"Nino","year":"2010","journal-title":"Dermatol. Online J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1089\/wound.2013.0503","article-title":"Epidermal Differentiation in Barrier Maintenance and Wound Healing","volume":"3","author":"Wikramanayake","year":"2014","journal-title":"Adv. Wound Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2018.03.018","article-title":"Anti-IL-12\/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis","volume":"828","author":"Takahashi","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.biomaterials.2011.11.011","article-title":"Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs","volume":"33","author":"Shah","year":"2012","journal-title":"Biomaterials"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cca.2008.04.005","article-title":"Cytokines and anticytokines in psoriasis","volume":"394","author":"Pietrzak","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00403-005-0602-8","article-title":"The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment","volume":"297","author":"Yazici","year":"2005","journal-title":"Arch. Dermatol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jid.2018.09.037","article-title":"Biological Effects of IL-26 on T Cell-Mediated Skin Inflammation, Including Psoriasis","volume":"139","author":"Itoh","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1046\/j.1365-2133.1997.01845.x","article-title":"Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis","volume":"136","author":"Creamer","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-4632.2011.05154.x","article-title":"The roles of cells and cytokines in the pathogenesis of psoriasis","volume":"51","author":"Coimbra","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2340\/00015555-2873","article-title":"Systemic Inflammation and Evidence of a Cardio-splenic Axis in Patients with Psoriasis","volume":"98","author":"Hjuler","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.phrs.2017.11.012","article-title":"Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-\u03b1\/IFN-\u03b3-induced inflammatory response in keratinocytes and T cell-derived IL-17","volume":"129","author":"Lin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1126\/science.8248808","article-title":"Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo","volume":"262","author":"Vaporciyan","year":"1993","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.imlet.2016.09.008","article-title":"Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris","volume":"181","author":"Wang","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1189\/jlb.1112562","article-title":"Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation","volume":"94","author":"Yanaba","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.4049\/jimmunol.1500551","article-title":"Dynamics and Transcriptomics of Skin Dendritic Cells and Macrophages in an Imiquimod-Induced, Biphasic Mouse Model of Psoriasis","volume":"195","author":"Terhorst","year":"2015","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2018.11.032","article-title":"Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases","volume":"555","author":"Carter","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopha.2018.07.156","article-title":"Understanding the prospective of nano-formulations towards the treatment of psoriasis","volume":"107","author":"Pradhan","year":"2018","journal-title":"Biomed. Pharmacother."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/9\/789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:04:11Z","timestamp":1760177051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/9\/789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["pharmaceutics12090789"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12090789","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}